PILERI, Alessandro
PILERI, Alessandro
Dip. MEDICINA ED ONCOLOGIA SPERIMENTALE (attivo dal 01/01/1900 al 30/04/2013)
IN MYELOMA PATIENTS TREATED WITH MELPHALAN 100mg/m2 OR MELPHALAN 200mg/m2 OUTCOME IS NOT SIGNIFICANTLY DIFFERENT
2000-01-01 Palumbo A; Triolo S; Bringhen S; Rus C; Omedè P; Bertola A; Giaccone L; Bianchi A; Bruno B; Tarella C; Caravita T; Musto P; Amadori S; Carotenuto M; Pileri A; Boccadoro M
INTERMEDIATE-DOSE CYCLOPHOSPHAMIDE FOLLOWED BY INTERFERON-ALPHA-2B AND PREDNISONE MAINTENANCE THERAPY FOR REFRACTORY MYELOMA
1994-01-01 PALUMBO A; BOCCADORO M; TRIOLO S; BRUNO B; FRIERI R; MAIRONE L; RAVIOLO E; LURASCHI A; INFELISE V; DARBESIO A; PILERI A
Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment
2007-01-01 Marco Ladetto; Federica De Marco; Fabio Benedetti; Umberto Vitolo; Caterina Patti; Alessandro Rambaldi; Alessandro Pulsoni; Maurizio Musso; Anna M. Liberati; Attilio Olivieri; Andrea Gallamini; Enrico Pogliani; Delia Rota Scalabrini; Vincenzo Callea; Francesco Di Raimondo; Vincenzo Pavone; Alessandra Tucci; Sergio Cortelazzo; Alessandro Levis; Mario Boccadoro; Ignazio Majolino; Alessandro Pileri; Alessandro M. Gianni; Roberto Passera; Paolo Corradini; Corrado Tarella
Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo)
2004-01-01 Marco Ladetto; Sonia Vallet; Paolo Corradini; Fabio Benedetti; Umberto Vitolo; Maurizio Martelli; Vincenzo Callea; Paolo Coser; Alessio Perrotti; Caterina Patti; Giuseppe Fioritoni; Sergio Morandi; Maurizio Musso; Renato Zambello; Monica Astolfi; Alessandro Pileri; Mario Boccadoro; Corrado Tarella
MOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE
2001-01-01 Bruno B; Ladetto M; Astolfi M; Sametti S; Veneziano L; Aitoro G; Giaccone L; Palumbo A; Pileri A; Boccadoro M; Storb R
REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS
2001-01-01 Ladetto M; Omedè P; Sametti S; Donovan JW; Drandi D; Giaccone L; Volpato F; Astolfi M; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M
REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM).
2000-01-01 Ladetto M; Omedè P; Sametti S; Donovan JW; Astolfi M; Giaccone L; Giaretta F; Volpato F; Bringhen S; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M.
Sequential cyclophosphamide-melphalan (CM) with circulating progenitor cell (CPC) support in multiple myeloma
1995-01-01 Boccadoro M; Palumbo A; Bruno B; Triolo S; Omede P; Argentino C; Pileri A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| IN MYELOMA PATIENTS TREATED WITH MELPHALAN 100mg/m2 OR MELPHALAN 200mg/m2 OUTCOME IS NOT SIGNIFICANTLY DIFFERENT | 2000 | Palumbo A; Triolo S; Bringhen S; Rus C; Omedè P; Bertola A; Giaccone L; Bianchi A; Bruno B; Tarella C; Caravita T; Musto P; Amadori S; Carotenuto M; Pileri A; Boccadoro M | |
| INTERMEDIATE-DOSE CYCLOPHOSPHAMIDE FOLLOWED BY INTERFERON-ALPHA-2B AND PREDNISONE MAINTENANCE THERAPY FOR REFRACTORY MYELOMA | 1994 | PALUMBO A; BOCCADORO M; TRIOLO S; BRUNO B; FRIERI R; MAIRONE L; RAVIOLO E; LURASCHI A; INFELISE V; DARBESIO A; PILERI A | |
| Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment | 2007 | Marco Ladetto; Federica De Marco; Fabio Benedetti; Umberto Vitolo; Caterina Patti; Alessandro Rambaldi; Alessandro Pulsoni; Maurizio Musso; Anna M. Liberati; Attilio Olivieri; Andrea Gallamini; Enrico Pogliani; Delia Rota Scalabrini; Vincenzo Callea; Francesco Di Raimondo; Vincenzo Pavone; Alessandra Tucci; Sergio Cortelazzo; Alessandro Levis; Mario Boccadoro; Ignazio Majolino; Alessandro Pileri; Alessandro M. Gianni; Roberto Passera; Paolo Corradini; Corrado Tarella | |
| Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo) | 2004 | Marco Ladetto; Sonia Vallet; Paolo Corradini; Fabio Benedetti; Umberto Vitolo; Maurizio Martelli; Vincenzo Callea; Paolo Coser; Alessio Perrotti; Caterina Patti; Giuseppe Fioritoni; Sergio Morandi; Maurizio Musso; Renato Zambello; Monica Astolfi; Alessandro Pileri; Mario Boccadoro; Corrado Tarella | |
| MOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE | 2001 | Bruno B; Ladetto M; Astolfi M; Sametti S; Veneziano L; Aitoro G; Giaccone L; Palumbo A; Pileri A; Boccadoro M; Storb R | |
| REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS | 2001 | Ladetto M; Omedè P; Sametti S; Donovan JW; Drandi D; Giaccone L; Volpato F; Astolfi M; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M | |
| REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM). | 2000 | Ladetto M; Omedè P; Sametti S; Donovan JW; Astolfi M; Giaccone L; Giaretta F; Volpato F; Bringhen S; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M. | |
| Sequential cyclophosphamide-melphalan (CM) with circulating progenitor cell (CPC) support in multiple myeloma | 1995 | Boccadoro M; Palumbo A; Bruno B; Triolo S; Omede P; Argentino C; Pileri A |